Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP14 | P50281 | 4/20 | 0.46 |
| ▸ | MMP8 | P22894 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP17 | Q9ULZ9 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543294 | 0.81 | LMNA (0.49) | MMP14MMP8GAAADAM17P2RX3 | |
| SCHEMBL29688652 | 0.79 | MMP14 (0.54) | MMP14MMP8MMP2MMP17MMP1 | |
| SCHEMBL20134812 | 0.79 | MMP14 (0.54) | MMP14MMP8MMP2MMP17MMP1 | |
| SCHEMBL543101 | 0.79 | KDM4E (0.41) | MMP14MMP8GAAMMP2MMP17 | |
| SCHEMBL20135060 | 0.74 | MMP14 (0.45) | MMP14MMP8MMP2MMP17MMP1 | |
| SCHEMBL29688624 | 0.70 | MMP14 (0.43) | MMP14MMP8MMP2MMP17MMP1 | |
| SCHEMBL20134755 | 0.69 | MMP14 (0.53) | MMP14MMP8MMP2MMP17MMP1 | |
| SCHEMBL3410690 | 0.69 | ADAM17 (0.60) | MMP14MMP8MMP2MMP17MMP1 | |
| SCHEMBL20135652 | 0.69 | ADAM17 (0.60) | MMP14MMP8MMP2MMP17MMP1 | |
| SCHEMBL20135513 | 0.69 | ADAM17 (0.60) | MMP14MMP8MMP2MMP17MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-8008306-B2 | Quinoline compounds | KOWA COMPANY, LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2272843-A1 | QUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100016327-A1 | QUINOLINE COMPOUNDS | KOWA COMPANY, LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | MMP14 1815/4885MMP8 701/4885GAA 2035/4885 |
| US-20100016327-A1 | QUINOLINE COMPOUNDS | NR1H2, NR1H3, LDLR | MMP14 2501/4885MMP8 1818/4885GAA 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.